Details

Autor(en) / Beteiligte

• Al-Hilal, Taslim A
• Keshavarz, Ali
• Kadry, Hossam
• Lahooti, Behnaz
• Al-Obaida, Ahmed
• Ding, Zhenya
• Li, Wei
• Kamm, Roger
• McMurtry, Ivan F
• Lahm, Tim
• Nozik-Grayck, Eva
• Stenmark, Kurt R
• Ahsan, Fakhrul

Titel

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application

Ist Teil von

• Lab on a chip, 2020-09, Vol.2 (18), p.3334-3345

Ort / Verlag

England: Royal Society of Chemistry

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Currently used animal and cellular models for pulmonary arterial hypertension (PAH) only partially recapitulate its pathophysiology in humans and are thus inadequate in reproducing the hallmarks of the disease, inconsistent in portraying the sex-disparity, and unyielding to combinatorial study designs. Here we sought to deploy the ingenuity of microengineering in developing and validating a tissue chip model for human PAH. We designed and fabricated a microfluidic device to emulate the luminal, intimal, medial, adventitial, and perivascular layers of a pulmonary artery. By growing three types of pulmonary arterial cells (PACs)-endothelial, smooth muscle, and adventitial cells, we recreated the PAH pathophysiology on the device. Diseased (PAH) PACs, when grown on the chips, moved of out their designated layers and created phenomena similar to the major pathologies of human PAH: intimal thickening, muscularization, and arterial remodeling and show an endothelial to mesenchymal transition. Flow-induced stress caused control cells, grown on the chips, to undergo morphological changes and elicit arterial remodeling. Our data also suggest that the newly developed chips can be used to elucidate the sex disparity in PAH and to study the therapeutic efficacy of existing and investigational anti-PAH drugs. We believe this miniaturized device can be deployed for testing various prevailing and new hypotheses regarding the pathobiology and drug therapy in human PAH. Current animal and cellular models only partially recapitulate the pathophysiology of PAH. Our PAH-on-a-chip model can mimic the major pathologies of PAH such as pulmonary arterial remodeling and sex disparity and help develop PAH therapeutics.